← Back to Search

Immunomodulator

Diphencyprone + Immunotherapy for Skin Cancer

Phase 1
Recruiting
Led By Nicholas Gulati, MD, PhD
Research Sponsored by Nicholas Gulati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject's oncologist plans as next standard of care treatment to use an FDA-approved PD-1 or PD-L1 ICI therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at day 98 or 128
Awards & highlights

Study Summary

This trial is testing a new way to treat cancer by combining two existing treatments. It will compare how well this new treatment works to the existing treatments, and also track any side effects.

Who is the study for?
Adults with skin cancer and at least three cutaneous (skin) metastases, who are planned to receive FDA-approved PD-1 or PD-L1 immune checkpoint inhibitors. They must be in a relatively stable condition (ECOG 0-2), able to consent, and use contraception. Excluded are those on certain other treatments like steroids, allergic to DPCP components, pregnant/nursing women, individuals with HIV or specific lymph node removals affecting the treatment area.Check my eligibility
What is being tested?
The study is testing the effect of a topical drug called Diphencyprone (DPCP) applied twice weekly for 12 weeks alongside standard immune checkpoint inhibitors. It aims to observe changes in gene expression in treated skin cancer metastases and document any adverse events from this combination therapy.See study design
What are the potential side effects?
Potential side effects include local skin reactions where DPCP is applied such as redness, itching or blistering. Systemic side effects may occur due to immune checkpoint inhibition which can range from flu-like symptoms to more serious conditions involving the lungs, liver, intestines, hormone glands or other organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My next treatment is an FDA-approved immune therapy.
Select...
I am able to care for myself and perform daily activities.
Select...
I am 18 years old or older.
Select...
I have skin cancer spread to at least three places that can be biopsied.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 98 or 128
This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 98 or 128 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects with a grade 3 adverse event

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diphencyprone (DPCP)Experimental Treatment1 Intervention
0.4% and 0.04% ointment

Find a Location

Who is running the clinical trial?

Nicholas GulatiLead Sponsor
1 Previous Clinical Trials
17 Total Patients Enrolled
Nicholas Gulati, MD, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
1 Previous Clinical Trials
17 Total Patients Enrolled
Philip Friedlander, MD, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
2 Previous Clinical Trials
5 Total Patients Enrolled

Media Library

Diphencyprone (DPCP) (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT05481658 — Phase 1
Metastases Research Study Groups: Diphencyprone (DPCP)
Metastases Clinical Trial 2023: Diphencyprone (DPCP) Highlights & Side Effects. Trial Name: NCT05481658 — Phase 1
Diphencyprone (DPCP) (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05481658 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining opportunities to join this experiment?

"Clinicaltrials.gov reveals that this particular clinical trial, first posted on the 1st of September 2022 and recently updated on the 28th of July 2022 is no longer open for enrolment. However, there are still 787 other medical trials searching for participants at present time."

Answered by AI

To what extent does Diphencyprone (DPCP) pose risk to participants?

"Due to the limited amount of data available for DPCP in regards to both safety and efficacy, our research team at Power rated it a 1 on the scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Nicholas Gulati 2022. "Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05481658.
~8 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top